# HTA dossier preparation Health-economic evidence packages — systematic clinical-evidence reviews, cost-effectiveness and budget-impact modeling, patient-perspective data — that a biopharma manufacturer must assemble to win pricing and reimbursement approval from a national HTA body (NICE, G-BA, CADTH), prepared by specialty consultancies against strict statutory deadlines (56 days for a NICE Single Technology Appraisal), increasingly using AI to compress a traditionally months-long process. Source: https://en.bioecon.ru/technology/hta-dossier-preparation/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: EU Joint Clinical Assessment (Regulation (EU) 2021/2282) | OECD: Biotech and health | Regulator: FDA (USA), EMA (EU), NMPA (China)] HTA dossier preparation assembles the health-economic evidence package a biopharma manufacturer must submit to a national health technology assessment body — NICE in the UK, G-BA in Germany, CADTH in Canada — to win a pricing and reimbursement decision after a drug or device already has regulatory marketing authorization. A NICE Single Technology Appraisal gives manufacturers a hard 56-calendar-day deadline to submit a full evidence dossier once scoping is complete, and Germany's AMNOG dossier for the G-BA carries similarly compressed timelines. One specialty consultancy has prepared over 370 HTA submission dossiers, more than 135 to NICE alone; another has built an in-house AI tool that compressed a full German AMNOG dossier's production time to three months. This is a distinct advisory service from the CMC regulatory filing and market-access manufacturing services already covered on this site — HTA dossier work happens after regulatory approval, building the separate economic case a payer needs to agree to reimburse the product, not the safety/efficacy case a regulator needs to approve it. Key directions of HTA dossier preparation: 1. **Systematic evidence review (Systematic Evidence Review):** structured literature reviews and network meta-analyses building the clinical comparator evidence base an HTA submission requires. 2. **Cost-effectiveness and budget-impact modeling (Cost-Effectiveness Modeling):** health-economic models calculating a therapy's cost-per-outcome and budget impact against national HTA methodology standards. 3. **AI-assisted dossier generation (AI-Assisted Dossier Generation):** AI tools that convert structured clinical trial data into the narrative sections an HTA dossier requires, compressing production timelines. 4. **Payer and HTA stakeholder engagement (Stakeholder Engagement):** structured advisory support for the negotiation and scientific-advice stages of an HTA submission process. ### Sectoral value chain ``` [regulatory marketing authorization] ──> [evidence synthesis] ──> [economic modeling] ──> [dossier assembly] │ (HTA body statutory deadline) │ ▼ [pricing/reimbursement decision] <─── [HTA body submission] <──┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Scoping** | defining the HTA submission's comparator and population scope | **In:** regulatory approval, target HTA body requirements. **Out:** submission scope document. | | **Evidence synthesis** | systematic review and network meta-analysis of clinical data | **In:** clinical trial data, published literature. **Out:** synthesized evidence base. | | **Economic modeling** | cost-effectiveness and budget-impact model construction | **In:** evidence base, cost data. **Out:** health-economic model outputs. | | **Dossier assembly** | compiling the full submission document per HTA body format | **In:** evidence, model outputs. **Out:** complete HTA dossier. | | **Submission & review** | formal submission and response to HTA body evidence requests | **In:** complete dossier. **Out:** HTA body evaluation, clarification responses. | | **Decision & negotiation** | pricing/reimbursement decision and any negotiated agreement | **In:** HTA evaluation. **Out:** reimbursement decision, price agreement. | Cross-cutting technologies: - **AI-assisted dossier generation (AI-Assisted Dossier Generation):** software converting structured clinical data into HTA-required narrative documentation. - **Cost-effectiveness modeling (Health-Economic Modeling):** statistical and economic models calculating cost-per-outcome against HTA methodology standards. - **AMNOG/NICE submission workflow (Statutory-Deadline Submission Workflow):** structured project-management processes built around each HTA body's specific statutory submission deadlines. --- ## US The US HTA landscape is shaped by a non-mandated but increasingly influential nonprofit assessor, with specialty consultancies built specifically around navigating its evidence expectations alongside private payer requirements. ### ICER's non-mandatory but influential role, AI-native and established consultancy models, private-payer evidence requirements - **Lumanity (Bethesda, founded 2020):** formed through the merger of several established health-economics and market-access firms including Cello Health and BresMed, with 1,200+ employees across the US, UK, Europe and India providing health-economics-and-outcomes-research services. - **VantEdge Access (Illinois, hubs in Chicago/Oak Brook and Paris):** combines AI-enabled HTA intelligence with consulting expertise across the US, Canada and EU-5 markets, supporting biopharma teams through development, launch and lifecycle market-access strategy. - **ICER's non-mandatory influence:** unlike NICE or other statutory HTA bodies, ICER's cost-effectiveness assessments are not mandated in the US, but its value-based price estimates increasingly shape payer negotiations and coverage decisions. --- ## CN No confirmed China-domiciled HTA-specialist consultancy was found operating independently; international consultancies with China offices serve manufacturers navigating the National Reimbursement Drug List process instead. ### NRDL as the reimbursement gateway, international-firm China offices, no confirmed domestic specialist - **NRDL as the reimbursement gateway:** inclusion on China's National Reimbursement Drug List, administered by the National Healthcare Security Administration, determines whether a product is reimbursed nationally and is often the only path to prescription within public hospitals. - **NHDRC evaluation role:** China's National Health Development Research Center provides technical HTA consultancy to health policy-makers, with a panel of health-economic experts scoring each eligible drug — a government research-institution role rather than a private-vendor service. - **International firms' China presence:** established international HTA consultancies maintain Shanghai offices to serve manufacturers navigating NRDL submissions, but no independently confirmed China-domiciled specialist firm was found — left qualitative pending a real candidate. --- ## EU Europe hosts the field's most established specialty consultancies, built around the UK's NICE and Germany's AMNOG processes, both running on strict statutory deadlines. ### NICE 56-day statutory deadline, AMNOG AI-compressed dossier production, B Corp-certified global consultancy model - **Costello Medical (Cambridge, UK):** a B Corp-certified consultancy with offices spanning Europe, Asia-Pacific and North America, having developed over 370 HTA submission dossiers with 135+ submitted to NICE alone, and winner of the King's Award for Enterprise in International Trade (2025). - **Kintiga (UK, ~90 employees):** a pan-European market-access consultancy whose in-house AI tool (EPRI) compressed a full German AMNOG HTA dossier's production to three months, alongside direct AMNOG negotiation support. - **NICE's 56-day statutory deadline:** manufacturers face a hard 56-calendar-day deadline to submit a full evidence dossier for a NICE Single Technology Appraisal once scoping concludes, the timeline pressure driving demand for specialty dossier-preparation services. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Costello Medical** | 🇬🇧 UK | *Full HTA evidence packages (strategy through dossier writing)* | 370+ HTA dossiers delivered, 135+ to NICE; B Corp certified; King's Award for Enterprise 2025 | Commercial | | **Kintiga** | 🇬🇧 UK | *EPRI AI-assisted AMNOG/NICE/JCA dossier tool* | AI-compressed AMNOG dossier production to 3 months; ~90 employees, 2 continents | Commercial | | **Lumanity** | 🇺🇸 USA | *HEOR and market-access advisory* | Formed 2020 via Cello Health/BresMed/Guidemark Health merger; 1,200+ employees | Commercial | | **VantEdge Access** | 🇺🇸 USA | *AI-enabled HTA intelligence platform* | US/Canada/EU-5 coverage; combines AI tooling with senior HEOR consulting | Commercial | --- ## Tech stack and innovations The category's technical work spans health-economic methodology and, increasingly, AI tooling that compresses the traditionally document-heavy dossier-writing process. 1. **Cost-effectiveness modeling infrastructure (Health-Economic Model Construction):** - Modelers build cost-effectiveness and budget-impact models specific to each HTA body's required methodology — NICE's reference-case requirements differ from G-BA's AMNOG framework, requiring jurisdiction-specific model construction rather than a single reusable template. - Network meta-analysis techniques let a dossier compare a therapy against multiple relevant comparators even when no direct head-to-head trial exists. 2. **AI-assisted dossier drafting (Structured-to-Narrative AI Conversion):** - AI tools convert structured clinical trial data directly into the narrative sections an HTA dossier's required format demands, compressing a process that traditionally took many months of manual medical writing. - This is a live technical differentiator: one firm's AI-assisted workflow completed a full AMNOG dossier in three months, a significantly compressed timeline versus traditional manual preparation. 3. **Statutory-deadline project management (Multi-Jurisdiction Submission Workflow):** - Firms operating across multiple HTA bodies manage genuinely different statutory deadlines and evidence-format requirements in parallel — a NICE STA's 56-day window differs from AMNOG's own compressed timeline — requiring dedicated project infrastructure rather than a single generic consulting workflow. --- ## Value chains and production pipelines ### Industrial pipeline of a NICE Single Technology Appraisal dossier ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Scoping │ ───> │ 2. Evidence synthesis │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Dossier assembly │ <─── │ 3. Economic modeling │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Submission │ ───> │ 6. Decision & negotiation │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Scoping The consultancy and manufacturer agree the submission's target population, comparator therapies and outcome measures based on the HTA body's published scoping document. #### Stage 2: Evidence synthesis A systematic literature review and network meta-analysis assembles the clinical evidence base, including indirect comparisons where no direct head-to-head trial against every relevant comparator exists. #### Stage 3: Economic modeling A cost-effectiveness and budget-impact model is built to the specific methodology the target HTA body requires, calculating cost-per-outcome and national budget impact. #### Stage 4: Dossier assembly Evidence synthesis and modeling outputs are compiled into the complete dossier document, in the exact format and section structure the HTA body mandates — increasingly assisted by AI tools that draft narrative sections from structured data. #### Stage 5: Submission The complete dossier is formally submitted within the HTA body's statutory deadline — 56 calendar days for a NICE STA following scoping — and the consultancy manages responses to any evidence clarification requests. #### Stage 6: Decision and negotiation The HTA body issues its pricing/reimbursement evaluation, with the consultancy supporting the manufacturer through any negotiation or appeal stage before a final reimbursement decision and price agreement.